Piribo: MedImmune: PharmaVitae Profile, new publication announcement

This analysis examines the historical and forecast performance for MedImmune in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase
- Benchmark MedImmune's performance against key rivals in the ethical pharmaceutical sector
- See how MedImmune will build on its Synagis success with the launch of follow-on product Numax, which is set to drive growth over the forecast period
- Evaluate the strategic benefits, in relation to its biotech peers, of MedImmune's focus on the high-growth infectious disease and oncology markets

Contents
Chapter 1 Executive Summary
Chapter 2 Corporate History
Chapter 3 Historical Performance
Chapter 4 Forecast Performance
Chapter 5 Key Products And Competitors
Chapter 6 Appendix

“MedImmune: PharmaVitae Profile” is available from Piribo. For more information go to: http://www.piribo.com/publications/pharmaceutical_companies/medimmune_pharmavitae_profile.html

Piribo Product ID: DAT556

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.